Co-founder, president and CEO of Venatorx Pharmaceuticals, Christopher J. Burns PhD, and co-founder and CEO of Spero Therapeutics, Ankit Mahadevia, have joined forces to publish a powerful opinion editorial in the Boston Herald.
Their article, ‘Pasteur Act can reinvigorate broken antibiotic market’, investigates how this legislation can work to prevent over-subscribing of antibiotics and incentivised development of novel antibiotics, during an escalating global public health crisis caused by drug-resistant infection.
A brief excerpt:
‘Researchers warn that without new antibiotics, drug-resistant infections could kill 10 million people annually by 2050. Currently, they kill 700,000 per year, worldwide, and contribute to an additional $4.6 billion in increased health care costs per year in the United States alone.’
It highlights the importance of continued R&D in this space – something Botanix is proud to be prioritising with our BTX 1801 development program.